Epidemiology, pathological characteristics and survival of retroperitoneal soft‑tissue sarcomas compared with non‑retroperitoneal soft tissue sarcomas
- Authors:
- Published online on: May 26, 2023 https://doi.org/10.3892/ol.2023.13887
- Article Number: 301
-
Copyright: © Buja et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Abstract
Retroperitoneal soft‑tissue sarcomas (RPS) are rare forms of mesenchymal tumors that account for ~0.15% of all malignancies. The purpose of the present study was to determine the differences between RPS and non‑RPS anatomopathological and clinical features and to analyze whether the hazard ratio for short‑term mortality differs between patients with RPS and non‑RPS, after adjusting for differences in baseline anatomopathological and clinical features. The Veneto Cancer Registry, a high‑resolution population‑based dataset spanning the regional population, was used as a data source for the analysis. The current analysis focuses on all incident cases of soft‑tissue sarcoma recorded by the Registry from January 1, 2017 to December 31, 2018. A bivariate analysis was carried out to compare demographic and clinical characteristics in RPS and non‑RPS. Short‑term mortality risk was analyzed by primary tumor site. The significance of variations in survival by site group was determined using Kaplan‑Meier curves and the Log‑rank test. Finally, Cox regression was used to assess the hazard ratio for survival by sarcoma group. RPS accounted for 22.8% of the total sample (92 out of 404 cases). The mean age at diagnosis was 67.6 years for RPS vs. 63.4 for non‑RPS; 41.3% of RPS were >150 mm vs. 5.5% for non‑RPS. Stages III and IV were more prevalent in RPS (53.2 vs. 35.6%), despite the fact that, in both groups, advanced stages are the most common onset at diagnosis. Regarding surgical margins, the present study showed that R0 is the most prevalent in non‑RPS (48.7%), while R1‑R2 is the most frequent in patients with RPS (39.1%). The 3‑year mortality rate for retroperitoneum was 42.9 vs. 25.7%. Comparing RPS and non‑RPS, the multivariable Cox model showed a hazard ratio of 1.58 after adjusting for all other prognostic factors. RPS clinical and anatomopathological characteristics differ from those of non‑RPS. Overall, despite adjusting for other prognostic factors, the retroperitoneum site was an independent prognostic factor associated with a worse overall survival in sarcoma patients compared with other sites.
